<h1>Wellness company marketing GLP-1-boosting capsule raises drug vs. supplement distinction under DSHEA and FD&C Act §343 risks</h1> A wellness company launched a capsule supplement marketed to support weight loss, metabolism and blood sugar by enhancing GLP-1 activity, positioning it as an affordable alternative to prescription GLP-1 drugs. Legally, this raises regulatory and liability considerations: whether product claims cross from permissible dietary-supplement claims into drug claims requiring regulatory approval; substantiation and clinical evidence standards under consumer protection and advertising laws; labeling and 'safe use' disclosures; potential misbranding or false-advertising risk if efficacy claims are unverified; and exposure to product-liability suits for adverse effects. Accurate clinical backing, clear disclaimers, and compliance with applicable drug, supplement and marketing regulations are advisable.